



Upcoming Medicaid Pharmacy Benefit Changes

Neighborhood News – April 2024

Effective **June 1, 2024**, Neighborhood Health Plan of Rhode Island's (Neighborhood) **Medicaid Pharmacy Benefit** will be making the following Formulary changes:

Admelog and **Apidra** products will be removed from the Medicaid Formulary. **Insulin Lispro** and **Insulin Aspart** products will be preferred.

- Medicaid members currently using Admelog and Apidra will require a new prescription for comparative Insulin Lispro or Insulin Aspart product.
- Insulin Lispro and Insulin Aspart products are available on the Medicaid Formulary and can be prescribed before **June 1, 2024**, to aid in the transition process for members.

Jardiance and **Invokana** will be removed from the Medicaid Formulary. **Generic dapagliflozin** becoming the preferred option.

- Medicaid members using Jardiance or Invokana will require a new prescription for dapagliflozin.
- Authorizations previously provided for Jardiance and Invokana will be terminated on **June 1, 2024**.
- If a member has been prescribed Jardiance or Invokana in the past 180 days, a new authorization for generic dapagliflozin is not needed.
- Generic dapagliflozin is on Neighborhood's Medicaid Formulary and can be prescribed on **June 1, 2024**, to aid in the transition process for members.

Note: These formulary changes do not apply to Neighborhood members with Commercial or INTEGRITY Insurance.